Clinical trial

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

NCT05494736

Study summary

ClinicalTrials.gov

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention MK-8527 Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-11-17

PhasePHASE1

Conditions

Human Immunodeficiency Virusunresolved

Interventions

MK-8527DRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Mapped research locations

JohannesburgGauteng, South Africa1 Cape TownWestern Cape, South Africa1 BloemfonteinFree State, South Africa1 BucharestBucharest, Romania1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05494736 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.